LUXEMBOURG--(BUSINESS WIRE)--Advanced Biological Laboratories (ABL) S.A., a Luxembourg-based MedTech company, today announced it has added DeepChek®-HIV to BaseSpace Apps, Illumina’s applications store and informatics community dedicated to advancing genomic analysis.
DeepChek®-HIV is a downstream analysis software for Next Generation Sequencing which offers a software solution for deep sequencing of HIV, from detection of HIV drug resistance variants to a comprehensive bioinformatics solution that provides inferred levels of resistance to major HIV-1 antiretroviral drugs through a simple report.
“The availability of DeepChek®-HIV in Illumina’s BaseSpace Apps is a new milestone for ABL’s innovative company and the DeepChek® platform. DeepChek®-HIV allows researchers to generate comprehensive reports of HIV variants and their impact on inferred levels of resistance from the newly published HIV pipeline of ABL,” said Dr. Chalom Sayada, CEO of ABL S.A. “We continue to develop new pipelines for virology, human genetics, bacteriology and oncology, including whole-genome analysis for HIV.”
Ultra-deep sequencing on Illumina’s MiSeq® desktop sequencer allows the identification of HIV nucleotide variants and variant haplotype signatures present at <1% in samples. Researchers can perform the analysis through the DeepChek® HIV pipeline once their samples are streamed from the instrument to BaseSpace. In addition, the DeepChek tracking of the viral population is very important as it can determine expressed dual infections in early stages of viral evolution, co-infection, or super infection and also drug resistance. The full workflow, with high-quality data processing, takes minutes to complete.
Informatics solutions available through BaseSpace Apps allow customers to utilize the tools from a growing community of academic, commercial, and open source providers.
About ABL
Advanced Biological Laboratories (ABL), S.A., is a
Medical Data Technology company founded in 2000 as a spin-off from
CRP-Santé Luxembourg. ABL took control of TherapyEdge, Inc. in 2004 and
in 2013 acquired the rights to all viral hepatitis B & C related assets
from EVIVAR MEDICAL, respectively. ABL has a comprehensive suite of
healthcare management tools, including TherapyEdge®, ViroScore®,
SeqHepB, DeepChek®, VisibleChek® and HepatiC™, which are used for data
and patient management, monitoring and personalized reporting
applications. In 2012, some of ABL's products received CE-marking for
IVD use. ABL's products offer infectious disease clinicians and virology
laboratories optimal and efficient IT solutions, for sequencing,
clinical genotyping, and drug resistance analysis, including powerful
fully integrated databases and analysis systems combining standard and
high-throughput Next Generation Sequencing data. DeepChek® on BaseSpace
Apps is for Research Use Only (RUO).
